KTTA · Pasithea Therapeutics Corp.

The appointment of Dr. Kartik Krishnan as Chief Medical Officer strengthens Pasithea's clinical leadership for advancing PAS-004, a next-generation MEK inhibitor, through clinical trials for neurofibromatosis type 1. His extensive 20+ years of experience, including key roles at Genentech where he contributed to the approval of cobimetinib—a relevant MEK inhibitor—and leadership positions at Arcus Biosciences and OncoNano Medicines, positions him to drive clinical development and regulatory strategy. Compensation includes a competitive $500,000 base salary, performance-based bonus potential, and significant equity incentives aligning his interests with shareholders. The concurrent Board approval of stock options to executives like Dr. Tiago Reis Marques (1,756,069 shares) and Daniel Schneiderman (1,129,323 shares), as well as non-employee directors (152,783 shares each), reflects efforts to align incentives with industry standards post-capital raises. No related-party arrangements or family ties disclosed.